Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 55,000 shares, a growth of 15.3% from the May 31st total of 47,700 shares. Based on an average daily volume of 7,100 shares, the short-interest ratio is presently 7.7 days. Currently, 2.0% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Eterna Therapeutics by 30.6% in the third quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock valued at $54,000 after acquiring an additional 5,830 shares in the last quarter. Sippican Capital Advisors raised its stake in shares of Eterna Therapeutics by 92.3% in the fourth quarter. Sippican Capital Advisors now owns 54,050 shares of the company’s stock valued at $97,000 after acquiring an additional 25,950 shares in the last quarter. Lake Street Advisors Group LLC acquired a new stake in shares of Eterna Therapeutics in the fourth quarter valued at $933,000. Finally, Avidian Wealth Solutions LLC acquired a new stake in shares of Eterna Therapeutics in the first quarter valued at $36,000. 70.55% of the stock is currently owned by institutional investors and hedge funds.

Eterna Therapeutics Price Performance

Shares of Eterna Therapeutics stock opened at $1.83 on Monday. Eterna Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $2.99. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 3.03. The stock has a 50 day moving average of $1.94 and a 200 day moving average of $1.91.

Eterna Therapeutics (NASDAQ:ERNA) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($1.23) earnings per share for the quarter. The company had revenue of $0.05 million during the quarter.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.